Active, not recruitingPhase 4NCT03229200
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Studying Lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pharmacyclics Switzerland GmbH
- Principal Investigator
- Kevin WuAbbVie
- Intervention
- Ibrutinib(drug)
- Enrollment
- 297 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2027
Study locations (30)
- Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center, Burbank, California, United States
- City Of Hope National Medical Center, Duarte, California, United States
- UCSD Moores Cancer Center, La Jolla, California, United States
- University of California Los Angeles (UCLA), Los Angeles, California, United States
- Stanford University, Stanford, California, United States
- Emory University, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Norton Medical Plaza II, 3991 Dutchmans Lane, Louisville, Kentucky, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Henry Ford Health System, Detroit, Michigan, United States
- TRIO - Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
- John Theurer Cancer Center, Hackensack UMC, Hackensack, New Jersey, United States
- San Juan Oncology Associates, Farmington, New Mexico, United States
- Northwell Health, New Hyde Park, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Janssen Biotech, Inc., including Johnson & Johnson
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03229200 on ClinicalTrials.govOther trials for Lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07511426U96-CAR-T-Cells For R/R B-ALLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07316010Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell LymphomaM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT07372352Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1, PHASE2NCT07575919Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALLLiping Dou
- ACTIVE NOT RECRUITINGPHASE1NCT07198087A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT07140016A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Astellas Pharma Global Development, Inc.
- RECRUITINGNANCT07191431A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）Ruijin Hospital
- RECRUITINGPHASE1, PHASE2NCT07018752A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasThe Lymphoma Academic Research Organisation